Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

BACKGROUND: Direct-acting antiviral (DAA) resistance-associated substitutions (RASs) can jeopardize the effectiveness of DAAs in patients with hepatitis C virus (HCV). The selection pressure by pegylated-interferon (Peg-IFN) plus ribavirin (P/R) treatment may enhance HCV genome variation. However, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zhi-wei, Pang, Xi-chen, Li, Zhao, Ren, Hong, Hu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587017/
https://www.ncbi.nlm.nih.gov/pubmed/28919791
http://dx.doi.org/10.2147/IDR.S145362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587017/
https://www.ncbi.nlm.nih.gov/pubmed/28919791
http://dx.doi.org/10.2147/IDR.S145362

Ejemplares similares